Medicines Co /de (MDCO): Hiroaki Shigeta , director of Medicines Co /de sold 3,849 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $38.50 per share for a total value of $148,186.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 13, 2016, Hiroaki Shigeta (director) sold 20,000 shares at $36.76 per share price.On Jun 10, 2016, Christopher T Cox (EVP & Chief Corp. Dev. Officer) purchased 45,985 shares at $37.62 per share price.Also, On May 26, 2016, Robert G. Savage (director) sold 10,000 shares at $36.95 per share price.On May 26, 2016, Melvin K Spigelman (director) sold 15,000 shares at $37.00 per share price.
The Medicines Company: On Monday, Jul 11, 2016 heightened volatility was witnessed in The Medicines Company which led to swings in the share price. The shares opened for trading at $34.91 and hit $39 on the upside , eventually ending the session at $36.19, with a gain of 3.70% or 1.29 points. The heightened volatility saw the trading volume jump to 39,91,704 shares. The 52-week high of the share price is $43.79 and the company has a market cap of $2,536 M . The 52-week low of the share price is at $27.5.
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products are: Angiomax (bivalirudin) Cleviprex (clevidipine) injectable emulsion Minocin (minocycline) for injection Orbactiv (oritavancin) PreveLeak and Recothrom Thrombin topical (Recombinant). The Company’s products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States cangrelor IONSYS (fentanyl iontophoretic transdermal system) Raplixa formerly referred to as Fibrocaps and RPX-602. The Company’s four research and development product candidates include ABP-700 ALN-PCSsc Carbavance and MDCO-216. The Company also develops ABP-700 an intravenous anesthetic which is in Phase I of clinical studies.